Overview
Lawsuits allege that Suboxone (buprenorphine/naloxone), a treatment for opioid use disorder, causes serious dental problems — including tooth decay, jaw pain and tooth loss. The FDA reported 305 dental adverse-event reports for buprenorphine products (131 serious) and required a label update in 2022 (per FDA). Individual product-liability claims are proceeding in multiple federal district courts, and a separate antitrust case exists (per dockets). As of August 2026 no global settlement has been announced (per firm pages).
Key people
Companies involved
Settlement amounts
No global settlement for the dental claims as of August 2026 (per firm pages). Individual cases proceed in various federal courts; amounts are case-specific. No outcome can be promised.
Key dates
- August 1, 2026Active intake: multiple plaintiff firms reviewing dental claims (per firm pages, Aug 2026)
- June 1, 2022FDA mandates label update adding dental risks to buprenorphine products (per FDA, 2022)
- January 15, 2022FDA safety communication on buprenorphine dental risks — 305 adverse-event reports, 131 serious (per FDA, 2022)
Updates
- Updated Sep 1, 2026Correction: dental injury cases are consolidated in MDL 3092 (N.D. Ohio, Judge Calabrese, per JPML), not pending as individual cases only.
- Updated Aug 1, 2026Seeded from research (Aug 2026): active intake by multiple plaintiff firms; FDA 305 dental adverse-event reports, 131 serious (per FDA, 2022).
Notable filings
No notable filings recorded yet. Docket entries are added from public court records as they appear.
FAQ
What is the Suboxone dental lawsuit about?
Claimants allege that Suboxone (buprenorphine/naloxone), a treatment for opioid use disorder, causes serious dental problems — including tooth decay, jaw pain, and tooth loss (per complaints). The federal cases are consolidated in MDL 3092, N.D. Ohio, before Judge J. Philip Calabrese (per JPML).
What did the FDA find?
The FDA reported 305 dental adverse-event reports for buprenorphine products (131 serious) and required a label update in 2022 (per FDA).
Is there an MDL?
Yes — the dental injury cases are consolidated in MDL 3092, In re Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, N.D. Ohio, before Judge J. Philip Calabrese (per JPML). A separate antitrust case also exists (per dockets).
Who is the defendant?
Reckitt, the manufacturer of Suboxone (per complaints and public records).
How much will victims receive?
No global settlement for the dental claims is on the public record as of August 2026 (per firm pages). Individual cases proceed in various federal courts; amounts are case-specific. No outcome can be promised.
How do I start a case review?
Use the free case review on this page. If you request it, your details are shared only with law firms working this matter. We are not a law firm and we do not promise any outcome.
Think this matters to you?
This page is neutral reference material — not legal advice. If you were affected, the next step is a free case review with a licensed attorney working this matter.
Start free case review →